Biogen pushes for broad CMS coverage of Alzheimer's drug — while Eli Lilly looks to escape an NCD

The nine-month quest for CMS to figure out how (or how not) to cover Biogen’s new Alzheimer’s drug Aduhelm, and potentially more amyloid-targeted monoclonal antibodies, kicked off in earnest on Tuesday with an open public hearing of comments from various stakeholders stressing the pros and cons of covering this new, pricey drug with unknown clinical benefits.